Share price of Aligos Therapeutics (NASDAQ:ALGS) rose 3.5%

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Your Free Report ) rose 3.5% during trading on Wednesday. The stock traded as high as $15.25 and last traded at $14.90. During trading, 12,972 shares were traded, down 40% from the session’s average volume of 21,559 shares. Shares previously closed at $14.39.

Analyst upgrades and downgrades

Separately, HC Wainwright assumed coverage on Aligos Therapeutics in a research note on Monday, August 19th. They issued a “buy” rating and a $75.00 price target for the company.

Check out our latest report on ALGS

Aligos Therapeutics Stock Performance

The stock has a fifty day moving average price of $13.29 and a 200 day moving average price of $16.47. The stock has a market cap of $1.11 billion, a PE ratio of -11.24 and a beta of 2.18.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report ) last announced its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping the consensus estimate of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The business had revenue of $1.06 million for the quarter. During the same period in the previous year, the company posted EPS of ($10.75). As a group, equities analysts anticipate that Aligos Therapeutics, Inc. will post -8.15 earnings per share for the current fiscal year.

Institutional Marketing of Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its stake in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after purchasing an additional 98,628 shares in the last quarter. Opaleye Management Inc. bought a new stake in shares of Aligos Therapeutics in the fourth quarter valued at $861,000. Altitude Crest Partners Inc. purchased a new stake in shares of Aligos Therapeutics during the fourth quarter valued at $1,889,000. Finally, Armistice Capital LLC bought a new position in shares of Aligos Therapeutics in the fourth quarter valued at about $4,538,000. Institutional investors own 60.43% of the company’s shares.

About Aligos Therapeutics

(Get a free report)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist, is in phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Read more

Get news and reviews for Aligos Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aligos Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.